Third Generation Sequencing Market Set to Witness Significant Growth by 2025-2032 | PacBio, Oxford Nanopore, BGI Genomics, Roche, Illumina, Thermo Fisher

The Third Generation Sequencing Market report underscores rapid shifts in sequencing technologies as laboratories and clinical centers accelerate adoption of long-read platforms. According to our market research, industry size expanded over 35% in 2024, driven by breakthroughs in single-molecule sequencing. These market insights highlight evolving industry trends, market dynamics, and business growth opportunities, setting the stage for robust market forecast through 2032.

Market Size and Overview-

The Global Third Generation Sequencing Market size is estimated to be valued at USD 881.4 million in 2025 and is expected to reach USD 3,366.5 million by 2032, exhibiting a compound annual growth rate (CAGR) of 21% from 2025 to 2032.

Request a Sample Copy of this Report at: https://www.coherentmarketinsights.com/insight/request-sample/5721

Key takeaways:

• North America: Continues as innovation hub with extensive research funding and regulatory support accelerating therapeutic sequencing initiatives.
• Latin America: Emerging adoption in genomic epidemiology, leveraging cost-effective run pricing to monitor infectious disease outbreaks.
• Europe: Holds leading industry share in clinical diagnostics, driven by EU grants and cross-border data-sharing policies.
• Asia Pacific: Fastest-growing region; governments in China and India ramp up capacity to enhance precision medicine and agriculture genomics.
• Middle East: Expanding genomics consortia pilot long-read platforms for rare disease diagnostics, supported by sovereign wealth fund investments.
• Africa: Development programs integrate portable sequencers for pathogen surveillance, addressing infrastructure constraints via mobile labs.
• Technology: SMRT and nanopore sequencing - SMRT led with 58% Third Generation Sequencing Market share in 2024 for full-length transcriptome analysis.

Market Segment:

• Application: Clinical diagnostics, agricultural genomics, and microbial profiling - clinical diagnostics drove 45% of runs in 2024.
• End-user: Pharmaceutical and biotech firms, academic institutes, and government labs - pharma companies invested USD 210 million in in-house capacity last year.

Growth Factors:

Key market drivers include the declining cost per base pair-slashed by 28% in 2024-enabling broader clinical adoption and fueling market growth in oncology and neurology applications. Expanding market opportunities in rare disease research drew USD 95 million in venture capital in 2024, while integrated multi-omics solutions broadened the market scope and elevated business growth. Third Generation Sequencing Market analysis shows throughput per flow cell climbed by 22% year-over-year, enhancing production capacity. Despite persistent market restraints such as sample preparation bottlenecks and instrument throughput limitations, automation investments and improved kit stability are expected to support sustained revenue acceleration and robust market drivers through 2032.

Get Full Report: https://www.coherentmarketinsights.com/market-insight/third-generation-sequencing-market-5721?utm_source=openpr.com&utm_medium=referral&utm

Market Trends:

Portable sequencing platforms continue to disrupt traditional lab models, with Oxford Nanopore's MinION command shipments up 34% in 2024, reflecting agile business growth approaches. Direct RNA sequencing workflows gained traction-accounting for 21% of runs-unlocking novel epitranscriptomic insights. Convergence of artificial intelligence and real-time base calling reduced error rates by 15%, addressing key market challenges and driving advanced market trends. Additionally, ecosystem partnerships-illustrated by Illumina and AI start-up collaborations-are shaping co-development of end-to-end pipelines, enhancing market growth strategies and reinforcing dynamic market dynamics for the Third Generation Sequencing Market.

Actionable Insights:

• Production Capacity: Installations of nanopore platforms reached 1,350 units globally in 2024, up 29% year-over-year.
• Pricing: Average cost per million bases dropped from USD 5 to USD 3.6 between 2023 and 2024, boosting affordability.
• Exports: China exported USD 120 million worth of sequencing equipment in 2024, representing 18% of Third Generation Sequencing Market revenue.
• Imports: European imports surged by 25% in Q3 2024 to meet demand in academic and clinical sectors.
• Use Cases: Clinical oncology applications drove 48% of total runs in 2024; agricultural genomics constituted 22%, expanding market segments.
• Nano-scale Indicators: Read accuracy improved by 12% with new chemistry kits, reducing post-processing time by 20%, underscoring expanding market size.

Key Players:

• Pacific Biosciences of California, Inc.
• Oxford Nanopore Technologies, Ltd.
• BGI Genomics Co., Ltd.
• F. Hoffmann-La Roche AG
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Agilent Technologies, Inc.
• GenapSys Inc.
• Loop Genomics
• Nabsys, Inc.
• Genia Technologies, Inc.

Competitive Strategies:

• Oxford Nanopore's direct RNA sequencing launch in 2024 fostered a 30% revenue uptick in portable sequencers.
• PacBio's HiFi chemistry upgrade improved read accuracy to 99.9%, attracting three major pharmaceutical partnerships and elevating instrument placements by 18%.
• BGI's collaboration with government genomics initiatives reduced per-sample costs by 15%, securing long-term contracts across Asia Pacific.

📌 Get Instant Access! Purchase Research Report and Receive a 25% Discount!
https://www.coherentmarketinsights.com/insight/buy-now/5721

FAQs:

1. Who are the dominant players in the Third Generation Sequencing Market?
PacBio, Oxford Nanopore, BGI Genomics, Roche, Illumina, Thermo Fisher, QIAGEN, and Agilent lead due to technology innovation and strategic collaborations.
2. What will be the size of the Third Generation Sequencing Market in coming years?
The market is projected to reach USD 3,366.5 million by 2032 at a CAGR of 21%, per our market forecast.
3. Which end-user industry has the largest growth opportunity?
Clinical diagnostics, particularly oncology and rare disease testing, is expected to capture the largest market segment through 2032.
4. How will market development trends evolve over the next five years?
Trends include AI-driven base calling, portable sequencing expansion, direct RNA workflows, and ecosystem partnerships enhancing throughput and accuracy.
5. What is the nature of the competitive landscape and challenges in the Third Generation Sequencing Market?
Competitive landscape is marked by rapid tech upgrades, price competition, and patent disputes; challenges encompass sample prep bottlenecks and data analysis complexity.
6. What go-to-market strategies are commonly adopted in the Third Generation Sequencing Market?
Key strategies involve product bundling, reagent-system integration, service model rollouts, and strategic alliances with academic and clinical organizations.

About Us:

With a proven excellence in market research, Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

☎️ Contact Us:

533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States
United States of America: + 12524771362
United Kingdom: UK Number: +442039578553
Australia: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com

This release was published on openPR.